Search company, investor...

Founded Year

2018

Stage

Incubator/Accelerator | Alive

Total Raised

$15.2M

About NEMIS Technologies

Nemis Technologies is a joint-venture between Biosynth and RAMOT, the Tel Aviv University business Engagement Center, established to develop diagnostic test kits based on the AquaSpark technology jointly developed and owned by Biosynth and Ramot.

Headquarters Location

Überlandstrasse 109

Dubendorf, 8600,

Switzerland

0041 44 820 71 52

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

NEMIS Technologies Patents

NEMIS Technologies has filed 3 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Bacterial toxins
  • Bioluminescence
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/24/2019

5/16/2023

Molecular biology, Bioluminescence, Luminescence, Chemical reactions, Biotechnology

Grant

Application Date

5/24/2019

Grant Date

5/16/2023

Title

Related Topics

Molecular biology, Bioluminescence, Luminescence, Chemical reactions, Biotechnology

Status

Grant

Latest NEMIS Technologies News

NEMIS Technologies raises CHF 7.75 million to further scale up its production and advance its internationalization strategy

Feb 7, 2022

NEMIS Technologies raises CHF 7.75 million to further scale up its production and advance its internationalization strategy  07.02.2022 12:55, Isabelle Mitchell NEMIS Technologies Ltd., amongst the Top 15 Swiss Biotech Startups of 2021, announces the closing of a CHF 7.75 million Series A financing round with the participation of both institutional and private investors. NEMIS specializes in fast, easy-to-use, affordable, and reliable on-site pathogen detection solutions. The company will use the investment to scale up its production, accelerate its ongoing international expansion, boost product development and relocate to new laboratory and office facilities in Au, ZH, Switzerland. NEMIS was a Venture Leader China in 2020 and one of the TOP 100 Swiss Startups in 2021. Arnaud Muller, NEMIS CEO, stated: “Following the great care and dedication of our team over the past year to rapidly industrialize and scale our production, the capital raised will enable us to accelerate our expansion in Europe and overseas. We also have the means to accelerate the development of additional diagnostic test kits and methods to further improve our offering, strengthen our organization in a targeted manner, and reach profitable growth. This would not be possible without the great trust from our partners and investors, for which we are very grateful.” Roger Meier, the Chairman of the Board, added: “In just three years, NEMIS has transformed itself from an interesting startup into a very dynamic and promising growth company with a value proposition that serves a rapidly growing need in an almost optimal way. We are very pleased that we were able to inspire different types of investors - from the extraordinarily successful company leader and entrepreneur to the international highly specialized, renowned Foodtech fund, who will accompany us on our further journey. With gratitude and confidence, we look forward to creating great benefit for our stakeholders.” About health challenges from foodborne pathogens Foodborne pathogens like Listeria Monocytogenes, Salmonella, E. Coli, and others can be found everywhere and are spreading rapidly throughout global food and supply chains. They make hundreds of thousands of consumers sick every year and can even be fatal. Contamination by microorganisms also causes huge amounts of food waste. Lastly, food manufacturers and distributors are increasingly confronted with product recalls, which cause not only immense financial costs but also major reputational damage to the companies concerned. By means of rapid detection and elimination, NEMIS is aiming at significantly reducing the health and cost burden of such pathogens to society.

NEMIS Technologies Frequently Asked Questions (FAQ)

  • When was NEMIS Technologies founded?

    NEMIS Technologies was founded in 2018.

  • Where is NEMIS Technologies's headquarters?

    NEMIS Technologies's headquarters is located at Überlandstrasse 109, Dubendorf.

  • What is NEMIS Technologies's latest funding round?

    NEMIS Technologies's latest funding round is Incubator/Accelerator.

  • How much did NEMIS Technologies raise?

    NEMIS Technologies raised a total of $15.2M.

  • Who are the investors of NEMIS Technologies?

    Investors of NEMIS Technologies include EIT Food RisingFoodStars and IMD Startup Competition.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.